ArticleBritish journal of clinical pharmacology2026
Unravelling the human disposition of [
Article in British journal of clinical pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Unravelling the human disposition of [British journal of clinical pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundVebreltinib is a novel, highly selective inhibitor of the hepatocyte growth factor receptor (HGFR, also known as c-MET or MET) tyrosine kinase under development for non-small cell lung cancer. This study aimed to characterize the absorption, metabolism, excretion and mass balance of [
methodsIn this open-label study, six healthy Chinese male subjects received a single 200 mg (100 μCi) oral dose of [
resultsVebreltinib was slowly absorbed, with a mean plasma elimination half-life of 20.1 ± 5.3 h. The half-life of total radioactivity was longer, consistent with the formation and persistence of metabolites. The mean total recovery of radioactivity was 93.0% ± 2.1%, with the majority recovered in faeces (79.5% ± 5.5% of the dose) and 13.5% ± 4.3% recovered in urine. Unchanged vebreltinib was the most abundant drug-related component in excreta, with the N-demethylated metabolite M2 as the major circulating metabolite.
conclusionFollowing oral administration, the predominant radioactive component recovered in faeces was unchanged parent drug. The quantitative metabolic profile confirms significant systemic exposure to the M2 metabolite. These data provide critical insights into the human disposition of vebreltinib, including a MIST assessment, and support its continued clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.